Granulomatous-Lymphocytic Interstitial Lung disease (GLILD) is a granulomatous and lymphoproliferative condition occurring in ~25% of Common Variable Immunodeficiency (CVID) patients with the highest prevalence in the late teen to young adult years. GLILD was first described in adults and carries a poor prognosis with survival estimated to be reduced by half. Here we report a pediatric case of CVID-associated GLILD that presented with rapid deterioration over 3 months and responded to adult-based treatment with dual chemotherapeutic agents (rituximab and azathioprine), resulting in complete resolution of clinical findings and near complete resolution of radiologic findings. This case highlights the opportunity to achieve a favorable outcome in GLILD following appropriate diagnosis and therapy.
CITATION STYLE
Tillman, R., Guillerman, R. P., Trojan, T., Silva-Carmona, M., & Chinn, I. K. (2019). Treatment-responsive Granulomatous-Lymphocytic Interstitial Lung disease in a pediatric case of common variable immunodeficiency. Frontiers in Pediatrics, 7(MAR). https://doi.org/10.3389/fped.2019.00105
Mendeley helps you to discover research relevant for your work.